thing appear go well oper base reaffirm guidanc
progress pbm integr remain sidelin strateg
direct unclear without perman ceo said board expect announc
appoint end week look construct long-term
strategi articul
board final stage ceo search process
dplo announc board final stage search process perman
ceo expect name next ceo end week interim ceo jeff park
voluntarili resign effect friday may although remain director cfo atul
kavthekar temporarili assum role ceo appoint next ceo
management note integr pbm busi good start dplo recent
rebrand launch pbm busi castiarx uniqu posit
serv small mid-siz payor specialti manag clinic care
capabl earli discuss broker pbm consult posit
notabl pbm busi perform in-lin management expect quarter
note pbm segment gener revenu net basi consist
management guidanc dplo realiz synergi re-affirmed
expect synergi lastli earli sell
season small mid-siz payor management note rfp volum pick
back half year
guidanc revenu revis reflect gross pbm revenu
management revis revenu guidanc due
applic new revenu recognit polici recogn pbm revenu
gross basi instead net otherwis revenu guidanc would remain unchang
management re-affirmed adj ebitda guidanc adj ep
weight averag share tax rate
thing appear go well oper base reaffirm guidanc
progress pbm integr remain sidelin strateg
direct unclear without perman ceo like share pressur
today despit in-lin quarter effect chang guidanc also well
like much street hope jeff park would name perman
ceo given track record ctrx acquir optumrx said
board expect announc appoint end week look
construct long-term strategi articul
pleas see page report import disclosur
remain sidelin given without perman ceo place strategi
compani unclear said larg posit dplo given macro tailwind
specialti well uniqu posit small mid-market pbm extens specialti
pharmaci servic capabl addit believ entranc pbm
help drive greater volum specialti pharmaci much like larger competitor
lastli compani appear execut integr recent pbm acquisit
new indic exist drug
addit new limit distribut
updat renewal/sel season
gross margin driven
better drug purchas
adj ebitda margin
top-lin growth rang
due better expect organ
growth acquisit
greater expect adj ebitda
margin strong oper leverag
top-lin growth teen due
greater expect declin hep
gross margin
lower expect adj ebitda margin
lack oper leverag lower
expect synergi
diplomat pharmaci largest independ specialti pharmaci unit state
compani focus specialti drug typic administ recur
basi treat patient complex chronic diseas requir special handl
administr part distribut process diplomat expertis across broad
rang high-growth specialti therapeut categori includ oncolog immunolog
hepat multipl sclerosi specialti infus therapi mani seriou and/
long-term condit compani servic includ assist complic
manag adher monitor diplomat partner lead biotechnolog
pharmaceut compani deliv custom support servic dispens new drug
updat estim price
rais adj ebitda estim
respect said lower price target
base revis dcf analysi impli share trade
adj ebitda estim current valuat
million except per-shar data
cowen compani
model assumptionstermin growth tax depreci chang work terminal- capit valuefre pv npv free npv futur excess valu total number valu per year end decemb cowen
million except per-shar data
compani report cowen compani
good gross gross chang sell gener administr adjust ebitda adjust adjust ebit chang fair valu redeem common shares- termin exist stock redempt agreement- equiti loss impair non-consolid entity- restructur impair charge- non-recurring incom incom incom tax tax amort acquisition-rel intang conting consider impair non-consolid entity- incom tax impact net incom alloc prefer shareholders- gaap net incom common dilut weight average common share adjust gaap chang year-over-year net incom net end decemb cowen
million except per-shar data
compani report cowen compani
good gross gross chang sell gener administr adjust ebitda adjust adjust ebit restructur impair charge- non-recurring incom incom incom tax tax net amort acquisition-rel intang conting consider impair non-consolid entity- incom tax impact net incom alloc prefer shareholders- gaap net incom common dilut weight average common share adjust gaap chang year-over-year net incom net cowen
million
compani report cowen compani
asset account receiv defer incom prepaid expens current total current properti equip capit softwar intern use definite-liv intang asset invest non-consolid defer debt issuanc non-current total current liabil account borrow line credit- short-term debt includ current portion long-term accru expens conting compens total current long-term debt less current conting consider less current portion- defer incom non-current liabilities- mandatorili redeem common shares- total stockhold equiti common addit paid-in retain total dplo sharehold non-controlling total sharehold total liabil stockhold short-term liquid ratio current sale purchas acct ratio inventori structur long-term solvenc ratio total debt total interest ratio return invest capit averag total asset averag stockhold equiti cowen
million
compani report cowen compani
flow oper activ depreci chang fair valu conting conting consider payment- net provis doubt share-bas compens defer incom tax impair capit softwar intern use- loss gain sale dispos properti excess tax benefit relat share-bas awards- amort debt issuanc chang oper asset liabil account account payabl asset net cash oper acquisit expenditur capit softwar intern expenditur issuanc common purchas treasuri stock- proceeds/ repay debt net increase/ decreas cash equival begin cash equival end cowen summari oper capit owner financ non-recur exclud non-recur itemsfor year end decemb cowen
million
compani report cowen compani
flow oper activ net adjust reconcil net incom net cash use oper activ depreci asset chang fair valu conting consideration- conting consider payment- net provis doubt share-bas compens equiti loss non-consolid defer incom tax expense- impair capit softwar intern use- loss gain sale dispos properti excess tax benefit relat share-bas awards- amort debt issuanc chang fair valu redeem common termin exist stock redempt agreement- certain expens paid notes- chang oper asset liabil account account payabl asset net cash use oper flow invest activ payment acquir busi net cash expenditur capit softwar intern expenditur properti capit invest loan non-consolid net cash use invest flow financ activ net payment line proce long-term debt- payment long-term proce public offer net transact costs- proce sale prefer stock net transact costs- payment made repurchas common stock- payment made repurchas stock options- proce issuanc stock upon stock option exercises- excess tax benefit relat share-bas awards- payment debt issuanc conting consider payments- sharehold net cash use provid financ net decreas increas cash equival begin period- equival end supplement disclosur cash flow inform paid paid incom taxes- year end decemb cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
potenti risk associ drug distribut space industri
highli competit could pressur margin core drug distribut busi
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind industri concern
around sustain high growth biotech sector longer term
impact ppaca expect increas volum could subdu depend
implement execut
number company-specif risk associ pt includ dplo
acquir significantli accret acquisit govern price control drug
suppli disrupt due relianc two supplier
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock diplomat pharmaci secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
